Tafasitamab
Based on 2 publication(s) in Google Scholar
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.71%
- CAS 番号: 1422527-84-1
- 分子量:147.42 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-P99113
InebilizumabAnti-CD19 mAb -
HY-P9913
RituximabCD20 Inhibitor -
HY-P99761
ObexelimabAnti-CD19 Antibody -
HY-P9966
EnoblituzumabB7-H3 mAb -
HY-P9963
BlinatumomabAntineoplastic Agent -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-70002
EnzalutamideAndrogen Receptor Antagonist -
HY-130149
AdagrasibKRAS G12C Inhibitor -
HY-P9910
Obinutuzumab (FUT8-KO)Anti-CD20 Antibody -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-132254
Sacituzumab govitecanTrop-2 ADC
MedChemExpress（MCE）の使用を引用している文献 Tafasitamab
More
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD19
体外実験
Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NHL cell lines and primary CLL and MCL cells by γδ T cells
-
Concentration:
-
Incubation Time:2 h
-
Result:Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.
-
Cell Line:SU-DHL-6 cells
-
Concentration:
-
Incubation Time:72 h
-
Result:Showed potent antiproliferative effects on tumor cell.
-
Cell Line:SU-DHL-6 cells
-
Concentration:0-4 ng/mL
-
Incubation Time:48 h
-
Result:Showed potent antiproliferative effects due to caspase-induced apoptosis
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Disseminated Raji model[1].
-
Dosage:2.5 μg/kg
-
Administration:Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
-
Result:Showed antitumor activity in disseminated Raji model.
-
Animal Model:Disseminated Ramos model[1].
-
Dosage:10 mg/kg
-
Administration:Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
-
Result:Showed antitumor activity in disseminated Ramos model.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-G2-kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC50 for this effect is 29.1 ng/mL. -
Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 95.42 and 117.87 ng/mL.
化学情報
-
CAS 番号 1422527-84-1
-
性状 Liquid
-
分子量 147.42 kDa
-
Color Colorless to light yellow
-
SMILES
[Tafasitamab]
-
別名
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
Clin Chem Lab Med
2025 Sep 15. PMID: 40965972
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. [Content Brief]
[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Tafasitamab 関連分類
HY-P9981 関連分類
Powered by Bioz